Literature DB >> 17504868

Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.

Bouke P C Hazenberg1, Martin H van Rijswijk, Marjolijn N Lub-de Hooge, Edo Vellenga, Elizabeth B Haagsma, Marcel D Posthumus, Pieter L Jager.   

Abstract

UNLABELLED: Serum amyloid P component (SAP) binds to amyloid. (123)I-SAP scintigraphy is used to evaluate the extent and distribution of amyloid in systemic amyloidosis and has great clinical value in the detection of systemic amyloidosis. The aim of the study was to assess during scintigraphy the diagnostic performance and prognostic value of a simple parameter describing extravascular (123)I-SAP retention in systemic amyloidosis.
METHODS: Two hundred megabecquerels of (123)I-labeled human SAP was injected intravenously for scintigraphy in 20 controls and in 189 consecutive patients with systemic and localized amyloidosis. Extravascular retention of (123)I-SAP was quantified from serum and urine measurements after 24 h (EVR(24)) and 48 h. Sensitivity and specificity were assessed, and retention was correlated with kidney, heart, liver, and nerve involvement and with survival.
RESULTS: The cutoff value representing a desired specificity of 90% of EVR(24) was 50%. The associated sensitivity of EVR(24) for detecting reactive systemic, immunocyte-derived (AL), and hereditary amyloidosis was 65%, 61%, and 22%, respectively, using a cutoff point of 50%. In AL amyloidosis, the EVR(24) increased with the number of organs involved (from a mean of 43% for 1 organ to a mean of 81% for 4 organs). The EVR(24) correlated with serum alkaline phosphatase (r = 0.63) and with creatinine clearance (r = -0.36). In AL amyloidosis, both cardiac involvement (hazard ratio, 3.9; 95% CI, 2.0-7.8) and EVR(24) (hazard ratio, 2.0; 95% CI, 1.1-3.9) were independent predictors of survival.
CONCLUSION: In AL amyloidosis, the EVR(24) is strongly associated with organ involvement and with prognosis and might serve as an indicator of the body amyloid load. Quantification of SAP retention using the EVR(24) has no additional value over (123)I-SAP scintigraphy in the detection of systemic amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504868     DOI: 10.2967/jnumed.106.039313

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

Review 1.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

2.  Imaging Findings and Literature Review of (18)F-FDG PET/CT in Primary Systemic AL Amyloidosis.

Authors:  Joo Hee Lee; Ga Yeon Lee; Seok Jin Kim; Ki Hyun Kim; Eun-Seok Jeon; Kyung-Han Lee; Byung-Tae Kim; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2015-05-13

Review 3.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

Review 4.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 5.  Treatment of immunoglobulin light chain amyloidosis.

Authors:  Morie A Gertz; Steven R Zeldenrust
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

Review 6.  Molecular imaging of amyloidosis: will the heart be the next target after the brain?

Authors:  Wengen Chen; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

7.  Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging.

Authors:  Ryogo Minamimoto; Kazuo Kubota; Kenji Ishii; Miyako Morooka; Momoko Okasaki; Yoko Miyata; Kazuhiko Nakajima; Takashi Sato; Toru Igari; Risen Hirai; Osamu Okazaki
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 8.  Nuclear imaging in cardiac amyloidosis.

Authors:  A W J M Glaudemans; R H J A Slart; C J Zeebregts; N C Veltman; R A Tio; B P C Hazenberg; R A J O Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-21       Impact factor: 9.236

Review 9.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

Review 10.  Amyloidosis of the Upper Aerodigestive Tract: Management of a Rare Disease and Review of the Literature.

Authors:  Thorsten Send; Jennifer L Spiegel; Goetz Schade; Annette Pantelis; Arno Olthoff; Friedrich Bootz; Martin Canis; Mark Jakob
Journal:  Dysphagia       Date:  2018-10-31       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.